Neuroendocrine Tumors Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | RayzeBio, Inc., Seneca Therapeutics, Vyriad, Inc., ADC Therapeutics, Eli Lilly and Company, Bi

Neuroendocrine Tumors Pipeline constitutes 100+ key companies continuously working towards developing 120+ Neuroendocrine Tumors treatment therapies, analyzes DelveInsight.

Neuroendocrine Tumors Overview:

Neuroendocrine cancer, also called a neuroendocrine tumor (NET) or neuroendocrine neoplasm, originates in the body's neuroendocrine cells, which share characteristics of both hormone-producing endocrine cells and nerve cells. These cells are found throughout the body and regulate various functions. Most NETs grow slowly over several years.

NETs can be classified as functional or nonfunctional based on hormone secretion. Functional tumors produce excess hormones, while nonfunctional ones either do not secrete hormones or do so at low levels, often without noticeable symptoms. Around 60% of NETs are nonfunctional, according to ASCO. Symptoms and treatment depend on the tumor type and hormone activity.

Since NETs do not have a consistent symptom profile, they are often detected incidentally through medical imaging or procedures for other conditions. If symptoms occur, they may result from tumor size, location, or hormone secretion, such as in carcinoid syndrome.

Request for a detailed insights report on Neuroendocrine Tumors pipeline insights @ https://www.delveinsight.com/report-store/neuroendocrine-tumors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Neuroendocrine Tumors Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Neuroendocrine Tumors Therapeutics Market.

Key Takeaways from the Neuroendocrine Tumors Pipeline Report

DelveInsight's Neuroendocrine Tumors pipeline report depicts a robust space with 100+ active players working to develop 120+ pipeline therapies for Neuroendocrine Tumors treatment.
In August 2024, Exelixis announced that the U.S. FDA accepted its supplemental New Drug Application (sNDA) for CABOMETYX. The application covers the treatment of adults with previously treated, locally advanced, unresectable, or metastatic pancreatic neuroendocrine tumors (pNET) and extra-pancreatic NET (epNET) that are well- or moderately differentiated. The FDA assigned a standard review with a Prescription Drug User Fee Act (PDUFA) target action date of April 3, 2025.
In July 2024, Curium submitted a 505(b)(2) New Drug Application (NDA) for Lutetium Lu 177 Dotatate Injection, intended for treating somatostatin receptor-positive (SSTR+) GEP-NETs.
In April 2024, Novartis announced that the U.S. FDA approved LUTATHERA for pediatric patients aged 12 and older with SSTR+ GEP-NETs, including tumors in the foregut, midgut, and hindgut.
Key Neuroendocrine Tumors companies such asRayzeBio, Inc., Seneca Therapeutics, Vyriad, Inc., ADC Therapeutics, Eli Lilly and Company, Biotheus Inc., ImmunityBio, Inc., Chimerix, Merck Sharp & Dohme, Oryzon Genomics S.A., CSPC ZhongQi Pharmaceutical Technology, TaiRx, Inc., Betta Pharmaceuticals, Pfizer, NanOlogy LLC, Cardiff Oncology, Luye Pharma Group, Philogen, Hoffmann-La Roche, Regeneron Pharmaceuticals, and others are evaluating new drugs for Neuroendocrine Tumors to improve the treatment landscape.
Promising Neuroendocrine Tumors pipeline therapies in various stages of development include RYZ101, SVV-001, Voyager-V1, ADCT-701, and others.

Neuroendocrine Tumors Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Neuroendocrine Tumors Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neuroendocrine Tumors treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Neuroendocrine Tumors market.

Download our free sample page report on Neuroendocrine Tumors pipeline insights @ https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Neuroendocrine Tumors Emerging Drugs

RYZ101: RayzeBio, Inc.
SVV-001: Seneca Therapeutics
Voyager-V1: Vyriad, Inc.
ADCT-701: ADC Therapeutics

Neuroendocrine Tumors Companies

Over 100 major companies are actively working on developing therapies for neuroendocrine tumors. Among them, RayzeBio, Inc. has a drug candidate in the most advanced stage of development, Phase III.

DelveInsight's report covers around 120+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Neuroendocrine Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Neuroendocrine Tumors Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Neuroendocrine Tumors Therapies and Key Companies: Neuroendocrine Tumors Clinical Trials and advancements @ https://www.delveinsight.com/report-store/neuroendocrine-tumors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Neuroendocrine Tumors Pipeline Therapeutic Assessment
• Neuroendocrine Tumors Assessment by Product Type
• Neuroendocrine Tumors By Stage
• Neuroendocrine Tumors Assessment by Route of Administration
• Neuroendocrine Tumors Assessment by Molecule Type

Download Neuroendocrine Tumors Sample report to know in detail about the Neuroendocrine Tumors treatment market @ Neuroendocrine Tumors Therapeutic Assessment @ https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Neuroendocrine Tumors Current Treatment Patterns
4. Neuroendocrine Tumors - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Neuroendocrine Tumors Late-Stage Products (Phase-III)
7. Neuroendocrine Tumors Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Neuroendocrine Tumors Discontinued Products
13. Neuroendocrine Tumors Product Profiles
14. Neuroendocrine Tumors Key Companies
15. Neuroendocrine Tumors Key Products
16. Dormant and Discontinued Products
17. Neuroendocrine Tumors Unmet Needs
18. Neuroendocrine Tumors Future Perspectives
19. Neuroendocrine Tumors Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Neuroendocrine Tumors Pipeline Reports Offerings: https://www.delveinsight.com/report-store/neuroendocrine-tumors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.